Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. [electronic resource]
Producer: 20090716Description: 401-13 p. digitalISSN:- 1351-0088
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Apoptosis -- drug effects
- Azacitidine -- therapeutic use
- Blotting, Western
- Caspase 3 -- metabolism
- Cell Proliferation -- drug effects
- Cisplatin -- administration & dosage
- Cyclin D1 -- metabolism
- Cyclin-Dependent Kinase Inhibitor p16 -- metabolism
- Cyclin-Dependent Kinase Inhibitor p21 -- metabolism
- Cyclin-Dependent Kinase Inhibitor p27 -- metabolism
- Disease Models, Animal
- Docetaxel
- Drug Synergism
- Drug Therapy, Combination
- Flow Cytometry
- Humans
- Male
- Mice
- Mice, Nude
- Prostatic Neoplasms -- drug therapy
- Proto-Oncogene Proteins c-bcl-2 -- metabolism
- Signal Transduction
- Taxoids -- administration & dosage
- Xenograft Model Antitumor Assays
- bcl-2 Homologous Antagonist-Killer Protein -- metabolism
- bcl-2-Associated X Protein -- metabolism
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.